Travere Therapeutics (TVTX) EBT Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 32.79% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 47.54% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -49.71% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 12.01% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 20.92% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -1.05% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | 27.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.53% |
| Dec 31, 2025 | 37.33% |
| Sep 30, 2025 | 32.12% |
| Jun 30, 2025 | 45.80% |
| Mar 31, 2025 | 20.41% |
| Dec 31, 2024 | 12.07% |
| Sep 30, 2024 | -15.49% |
| Jun 30, 2024 | -21.32% |
| Mar 31, 2024 | -36.35% |
| Dec 31, 2023 | 10.16% |
| Sep 30, 2023 | -58.22% |
| Jun 30, 2023 | -57.64% |
| Mar 31, 2023 | -74.47% |
| Dec 31, 2022 | -41.46% |
| Sep 30, 2022 | -31.37% |
| Jun 30, 2022 | -27.45% |
| Mar 31, 2022 | -26.27% |
| Dec 31, 2021 | -128.35% |
| Sep 30, 2021 | 13.02% |
| Jun 30, 2021 | -20.69% |
| Mar 31, 2021 | -43.43% |
| Dec 31, 2020 | -122.81% |
| Sep 30, 2020 | -5.81% |
| Jun 30, 2020 | -19.72% |
| Mar 31, 2020 | -11.37% |
| Dec 31, 2019 | -34.99% |
| Sep 30, 2019 | -6.49% |
| Jun 30, 2019 | -22.93% |
| Mar 31, 2019 | -104.90% |
| Dec 31, 2018 | 16.91% |
| Sep 30, 2018 | -33.42% |
| Jun 30, 2018 | 4.58% |
| Mar 31, 2018 | -267.39% |
| Dec 31, 2017 | 27.55% |
| Sep 30, 2017 | -1.89% |
| Jun 30, 2017 | -53.73% |
| Mar 31, 2017 | 44.19% |
| Dec 31, 2016 | 1.22% |
| Sep 30, 2016 | -36.65% |
| Jun 30, 2016 | -61.64% |
| Mar 31, 2016 | 48.32% |